CohBar Inc. to Webcast, Live, at VirtualInvestorConferences.com February 2
Company invites individual and institutional investors to attend interactive real-time virtual VirtualInvestorConferences.com
NEW YORK, Feb. 1, 2017 /PRNewswire/ -- CohBar Inc. (OTCQX: CWBR and TSXV: COB.U), a Menlo Park, CA based biotechnology company focused on developing mitochondria-based therapeutics (MBTs) to treat diseases associated with aging, today announced that the Company's CEO Simon Allen will present live at VirtualInvestorConferences.com on February 2, 2017.
DATE: Thursday, February 2, 2017
TIME: 2:30pm ET
This will be a live, interactive online event where investors are invited to ask the company questions in real-time - both in the presentation hall as well as the association's "virtual trade booth." If attendees are not able to join the event live on the day of the conference, an on-demand archive will be available for 90 days.
It is recommended that investors pre-register and run the online system check to save time and receive event updates.
Learn more about the event at www.VirtualInvestorConferences.com.
Recent Company Highlights
- During the fourth quarter of 2016, CohBar Inc. announced the discovery of a large number of new biologically active peptides encoded within the mitochondrial genome and the filing of over 50 additional related provisional patent applications.
- In September 2016, CohBar Inc. announced the selection of two analogs from the company's MOTS-c program for advancement into IND-enabling activities. The drug candidates, CB4209 and CB4211, demonstrated significant therapeutic potential in pre-clinical models for the treatment of obesity, with additional confirmatory studies planned to determine therapeutic potential for the treatment of nonalcoholic steatohepatitis (NASH), and as a potential add-on to other drugs for the treatment of type 2 diabetes.
CohBar (OTCQX: CWBR and TSXV: COB.U) is a preclinical stage biotechnology company focused on the research and development of mitochondria based therapeutics (MBTs), an emerging class of drugs for the treatment of age-related diseases. MBTs originate from the discovery by CohBar's founders of a novel group of peptides within the mitochondrial genome, which regulate metabolism and cell death and whose biological activity declines with age. CohBar's efforts focus on the development of these mitochondrial-derived peptides (MDPs) into clinically relevant MBTs that offer the potential to address a broad range of age-related diseases, including obesity, fatty liver disease, Type-2 diabetes, cancer, cardiovascular and neurodegenerative disorders. To date, the Company and its founders have discovered more than 50 biologically active mitochondrial peptides.
About CohBar's Clinical Development Program
CohBar's lead clinical development program is based on MOTS-c, a mitochondrial-derived peptide discovered in 2012 by the Company's founders and their academic collaborators, whose research has shown that MOTS-c plays a significant role in the regulation of metabolism. The Company has developed optimized analogs of the MOTS-c peptide, CB4209 and CB4211, as drug candidates for advancement into IND-enabling activities. These drug candidates have demonstrated significant therapeutic potential in preclinical models for the treatment of obesity, with additional ongoing studies to determine their therapeutic potential for the treatment of nonalcoholic steatohepatitis (NASH), an advanced form of fatty liver disease, and as an add-on to other drugs for the treatment of Type-2 diabetes.
For additional information, please visit www.cohbar.com.
Since 2010, VirtualInvestorConferences.com, created by BetterInvesting (NAIC) and PRNewswire, has been the only monthly virtual investor conference series that provides an interactive forum for presenting companies to meet directly with investors using a graphically-enhanced online platform. Designed to replicate the look and feel of location-based investor conferences, Virtual Investor Conferences unites PR Newswire's leading-edge online conferencing and investor communications capabilities with BetterInvesting's extensive retail investor audience network.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/cohbar-inc-to-webcast-live-at-virtualinvestorconferencescom-february-2-300399635.html
SOURCE CohBar Inc.
Released February 1, 2017